Valuation: TScan Therapeutics, Inc.

Market Cap 82.34M 72.22M 66.68M 61.62M 117M 7.88B 119M 802M 311M 3.86B 309M 302M 13.39B P/E 2026 *
-1.44x
P/E 2027 * -1.37x
Enterprise Value -16.53M -14.49M -13.38M -12.37M -23.44M -1.58B -23.91M -161M -62.5M -774M -62.06M -60.7M -2.69B EV / Sales 2026 *
-2.19x
EV / Sales 2027 * 0.97x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -
06-22 TScan Therapeutics Presents Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation CI
06-22 TScan Therapeutics Reports Positive Data From Trial of Blood Cancer Treatment MT
06-03 Cellares and TScan Therapeutics Inc. Announce Agreement To Evaluate Automated Manufacturing Of TSC-101 CI
05-06 TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-02 TScan Therapeutics, Inc. Announces Executive Changes, Effective April 10, 2026 CI
03-04 TScan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
02-27 TScan Therapeutics completes enrollment in cohort C of Phase 1 Alloha(TM) trial RE
02-26 TScan Therapeutics, Inc. Completes Enrollment in Cohort C of Phase 1 AlloHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A03 CI
12-19 TScan Therapeutics, Inc.(NasdaqGM:TCRX) dropped from NASDAQ Biotechnology Index CI
12-07 TScan Therapeutics Announces Positive Updated Data from the AlloHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition CI
11-14 Morgan Stanley Downgrades TScan Therapeutics to Equalweight From Overweight MT
11-12 TScan Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-12 TScan Therapeutics Q3 revenue jumps RE
1 day+17.76%
1 week+17.76%
Current month+28.56%
1 month+26.77%
3 months+18.87%
6 months+6.78%
Current year+26.00%
1 week 1.01
Extreme 1.01
1.28
1 month 0.83
Extreme 0.8251
1.28
Current year 0.83
Extreme 0.8251
1.47
1 year 0.83
Extreme 0.8251
2.57
3 years 0.83
Extreme 0.8251
9.69
5 years 0.83
Extreme 0.8251
14.71
10 years 0.83
Extreme 0.8251
14.71
Manager TitleAgeSince
Chief Executive Officer 56 28/03/2023
Director of Finance/CFO 57 29/01/2024
Chief Tech/Sci/R&D Officer - 06/02/2024
Director TitleAgeSince
Director/Board Member 68 23/03/2021
Director/Board Member 56 24/05/2023
Chairman 55 12/06/2024
Date Insider Type Main position Quantity % Market Cap.
05-20Free

Director

67,000 0.1200%
05-20Free

Director

67,000 0.1200%
05-20
Baker Bros. Advisors LP
FreeCompany 134,000 0.2400%
Change 5-day change 1-year change 3-year change Capi.($)
+17.76%+17.76%-25.88%-45.22% 82.34M
-0.23%-3.34%+71.53%+126.85% 56.71B
-2.45%-7.83%+63.92%+83.15% 51.3B
+3.27%+8.91%+21.21%+486.76% 25.26B
-0.81%-0.42%-16.24%-12.47% 23.65B
+3.93%+3.35%+43.09%-2.47% 18.69B
-0.33%+0.59%+37.44%-26.22% 17.71B
+2.34%+12.50%+224.02%+380.99% 17.7B
-0.92%+1.58%+35.79% - 14.26B
-1.70%+3.98%+28.96%+190.57% 14.1B
Average +2.18%+5.39%+48.38%+131.33% 23.95B
Weighted average by Cap. +0.08%+2.20%+57.78%+143.76%

Financials

2026 *2027 *
Net sales 7.56M 6.63M 6.12M 5.66M 10.72M 724M 10.93M 73.57M 28.59M 354M 28.38M 27.76M 1.23B 7.81M 6.85M 6.32M 5.84M 11.07M 748M 11.29M 76M 29.53M 366M 29.32M 28.68M 1.27B
Net income -115M -101M -93.18M -86.11M -163M -11.02B -166M -1.12B -435M -5.39B -432M -423M -18.72B -125M -109M -101M -93.4M -177M -11.95B -181M -1.22B -472M -5.85B -469M -458M -20.3B
Net Debt -98.87M -86.72M -80.06M -73.98M -140M -9.47B -143M -962M -374M -4.63B -371M -363M -16.08B -74.76M -65.57M -60.53M -55.94M -106M -7.16B -108M -728M -283M -3.5B -281M -275M -12.16B
Logo TScan Therapeutics, Inc.
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Employees
139
Date Price Change Volume
08/07/26 $1.260 +17.76% 2,637,071
07/07/26 $1.070 +1.90% 606,643
06/07/26 $1.050 -0.94% 418,939
02/07/26 $1.060 -0.93% 879,505
01/07/26 $1.070 +9.17% 1,680,656
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.260USD
Average target price
6.000USD
Spread / Average Target
+376.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRX Stock